摘要
目的分析促红细胞生成素在血液病贫血及肾性贫血治疗中的应用效果。方法72例血液病贫血、肾性贫血患者,按照病情等级、不同病因病情均分为观察组及对照组,每组36例。观察组患者接受重组人促红素注射液(CHO细胞)治疗,对照组患者接受多糖铁复合物胶囊治疗。对比两组患者的治疗效果,血红蛋白及红细胞提升率,不良事件发生情况。结果观察组患者的治疗总有效率97.22%高于对照组的75.00%,差异具有统计学意义(P<0.05)。观察组患者治疗后3 d、1周、2周的血红蛋白提升率分别为(1.59±0.47)%、(6.08±1.26)%、(12.29±2.67)%,红细胞计数提升率分别为(0.98±0.54)%、(5.79±1.51)%、(11.86±2.34)%;对照组患者治疗后3 d、1周、2周的血红蛋白提升率分别为(0.63±0.29)%、(4.25±1.09)%、(8.13±1.81)%,红细胞计数提升率分别为(0.46±0.27)%、(3.73±1.11)%、(7.81±1.18)%。观察组患者治疗后3 d、1周、2周的血红蛋白提升率、红细胞计数提升率均高于对照组,差异具有统计学意义(P<0.05)。观察组患者的不良事件发生率2.78%低于对照组的16.67%,差异具有统计学意义(P<0.05)。结论促红细胞生成素治疗血液病贫血、肾性贫血的疗效均显著,能提升血红蛋白、红细胞计数水平,不良事件发生率低,值得临床推广应用。
Objective To study the application effect of erythropoietin in the treatment of hemopathic anemia and renal anemia.Methods A total of 72 patients with hemopathic anemia and renal anemia were divided into observation group and control group according to disease grade and different etiology,with 36 cases in each group.The observation group was treated with recombinant human erythropoietin injection(CHO cells),and the control group was treated with iron polysaccharide complex capsule.The therapeutic effects,increase rates of hemoglobin and red blood cell and adverse events were compared between the two groups.Results The total effective rate of the observation group was 97.22%,which was higher than that of 75.00%of the control group,and the difference was statistically significant(P<0.05).After 3 d,1 week and 2 weeks of treatment,the increase rates of hemoglobin of the observation group were(1.59±0.47)%,(6.08±1.26)%and(12.29±2.67)%,and the increase rates of red blood cell count were(0.98±0.54)%,(5.79±1.51)%and(11.86±2.34)%,respectively.After 3 d,1 week and 2 weeks of treatment,the increase rates of hemoglobin of the control group were(0.63±0.29)%,(4.25±1.09)%and(8.13±1.81)%,and the increase rates of red blood cell count were(0.46±0.27)%,(3.73±1.11)%and(7.81±1.18)%,respectively.After 3 d,1 week and 2 weeks of treatment,the increase rates of hemoglobin and red blood cell count of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse events in the observation group was 2.78%,which was lower than that of 16.67%in the control group,and the difference was statistically significant(P<0.05).Conclusion The efficacy of erythropoietin in the treatment of hemopathic anemia and renal anemia is confirmed,which can enhance hemoglobin and red blood cell count,with low incidence of adverse reactions,which is worthy of clinical promotion.
作者
王引舟
邱兰云
邱璐茜
黄香兰
WANG Yin-zhou;QIU Lan-yun;QIU Lu-xi(Fujian Sanming Second Hospital East Hospital,Sanming 366000,China)
出处
《中国现代药物应用》
2023年第16期18-21,共4页
Chinese Journal of Modern Drug Application
